Adverse hepato-biliary-pancreatic events in acromegaly patients treated with first generation somatostatin receptor ligands
Authors' conclusion
Hepato-biliary-pancreatic adverse events are not infrequent during long-term SRLs therapy and are influenced overall by older age, cholelithiasis and biliary sludge.
Study context
- Population
- Acromegaly patients treated with first-generation somatostatin receptor ligands (SRLs), followed from start of SRL therapy (T0) to last follow-up (120 ± 97.31 months); 223 females
- Participants
- 371 patients
- Outcome
- Prevalence and predictors of hepato-biliary-pancreatic adverse events during SRL treatment
- Follow-up
- Last visit (120 ± 97.31 months)
Methodological detailsmulticentre, Data collected retrospectively
- Multicentre
- Data collected retrospectively
Main finding
As reported in the abstract
Prevalence of hepato-biliary-pancreatic adverse events · last follow-up (120 ± 97.31 months)
- Cholecystectomy (CH-Tx)
- 61 (16.4%)
- Cholecystitis (CH)
- 3.8%
- Severe hyperlipasemia/hyperamylasemia
- 2.2%
- Mild hyperlipasemia/hyperamylasemia
- 5.1%
- Severe hypertransaminasemia
- 1.1%
- Mild hypertransaminasemia
- 6.4%
Observational data: associations, not effects.
Further findings
- Higher prevalence of cholelithiasis at T0 in CH-Tx and CH
- P = 0.002 and p = 0.005
- Independent predictors of cholecystectomy: cholelithiasis; biliary sludge
- P = 0.040; p = 0.014
- Cholelithiasis predicted cholecystitis, univariable; multivariable
- P = 0.012; p = 0.025
- Ursodeoxycholic acid (UDCA) treatment associated with cholecystitis; mild hypertransaminasemia
- P = 0.007; p = 0.035
- Overall adverse events, univariate predictors: cholelithiasis, biliary sludge, age at T0
- P = 0.006,p = 0.010,p = 0.013
- Overall adverse events, multivariable predictors: cholelithiasis, biliary sludge, age at T0
- P = 0.029,p = 0.028,p = 0.044
- No significant differences by gender or age (≤/>50yrs)
- BMI, GH and IGF1 not associated with higher risk of biliary complications
Original publication
Adverse hepato-biliary-pancreatic events in acromegaly patients treated with first generation somatostatin receptor ligands. Pituitary. Published 4 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →